219496-61-4

Basic information

• Product Name: L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester
• CAS NO: 219496-61-4
• Molecular Formula: C22H24Cl2N2O5
• Molecular Weight: 467.349
• Mol File: 219496-61-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester(219496-61-4)
• EPA Substance Registry System: L-Phenylalanine, 4-[(2,6-dichlorobenzoyl)amino]-N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester(219496-61-4)

Safety Data

• Hazardous Substances Data: 219496-61-4(Hazardous Substances Data)

Upstream product

• 65615-90-9 (S)-methyl 3-(4-aminophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 4659-45-4 2,6-Dichlorobenzoyl chloride 
• 33305-77-0 Boc-Phe(p-NO₂)-OH 
• 65615-89-6 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propanoate 

Downstream Products

• 220880-36-4 (S)-2-[[1-(2-azido-ethyl)-cyclopentanecarbonyl]-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid methyl ester 
• 220878-78-4 (S)-2-[[1-(2-amino-ethyl)-cyclopentanecarbonyl]-amino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid 
• 220877-86-1 (S)-2-[[[1-(2-amino ethyl)cyclopentyl]carbonyl]amino]-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid methyl ester 
• 220848-54-4 4-[[(2,6-dichlorophenyl)carbonyl]amino]-N-[[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]sulfonyl]phenyl]carbonyl]-L-phenylalanine methyl ester 
• 220848-44-2 (S)-2-[2-Chloro-4-(3-hydroxy-benzylcarbamoyl)-benzoylamino]-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid methyl ester 
• 220846-23-1 (S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(2-fluoro-6-trifluoromethyl-benzoylamino)-propionic acid methyl ester 

Relevant articles and documents

Lipid Compounds Targeting VLA-4

The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4

The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.

INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION

-